Please assess the completion status of the following clinical trial:

Trial Title: Microbiota Restoration Therapy in HIV With Repeated Low-Dose Interventions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* On stable antiretroviral therapy with plasma HIV RNA \<20 copies/mL during at least 48 weeks.~* CD4/CD8 ratio \<1~Exclusion Criteria:~* Pregnancy~* Gastrointestinal diseases, including cirrhosis~* Active infections, including HCV~* EBV and/or CMV negative patients (donors are not screened for EBV/CMV).~* Planned used of chemotherapy or antibiotics~* Allergy to sodium chloride or glycerol (the former components are capsule ingredients Generally Recognized As Safe (GRAS)~* Current or planned use of antimicrobial agents (including prophylactic treatments against P. jiroveci) other than ART.~* Neutropenia \<500 cells/uL or CD4 counts \<350 cells/uL~* Patients unable to give informed consent~* Patients unable to comply with the protocol requirements~* Predicted death within time period of follow-up~* Any other condition for which the treating physician thinks the treatment may pose a health risk~* Dysphagia: oropharyngeal, esophageal, functional, neuromuscular (e.g. stroke, multiple sclerosis, ALS)~* History of aspiration~* History of gastroparesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- FMT (Type: EXPERIMENTAL): Fecal microbiota capsules (provided by Openbiome).~Dosage:~* Induction: 10 capsules (single dose)~* Maintenance: 5 capsules, weekly, during 7 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules (provided by Openbiome).~Dosage:~* Induction: 10 capsules (single dose)~* Maintenance: 5 capsules, weekly, during 7 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).